Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors

Pathology Research and Practice

Volumn 207, Issue 10, 2011, Pages 634-639

  Kwon, Mi Jung ^a   Choi, Yoon La ^b   Sung, Ki Woong ^b   Kang, So Young ^b   Park, Sang Mo ^b,d   Choi, Song Yi ^c   Kim, Jung Sun ^b   Suh, Yeon Lim ^b  

^a Hallym University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Chungbuk National University Hospital   (South Korea)

^d Soonchunhyang University   (South Korea)

Author keywords

Anaplastic lymphoma kinase; Mutation; Neuroblastoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; GENOMIC DNA;

ADOLESCENT; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; ONCOGENE; POLYMERASE CHAIN REACTION; PREVALENCE; SEQUENCE ANALYSIS; SURVIVAL RATE; TUMOR LOCALIZATION;

ADOLESCENT; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KOREA; MALE; MUTATION; NEOPLASM STAGING; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 80755132264     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.07.011     Document Type: Article

References (19)

1. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
2. Coluccia A.M., Gunby R.H., Tartari C.J., Scapozza L., Gambacorti-Passerini C., Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin. Ther. Targets 2005, 9:515-532.
3. De Brouwer S., De Preter K., Kumps C., Zabrocki P., Porcu M., Westerhout E.M., Lakeman A., Vandesompele J., Hoebeeck J., Van Maerken T., De Paepe A., Laureys G., Schulte J.H., Schramm A., Van Den Broecke C., Vermeulen J., Van Roy N., Beiske K., Renard M., Noguera R., Delattre O., Janoueix-Lerosey I., Kogner P., Martinsson T., Nakagawara A., Ohira M., Caron H., Eggert A., Cools J., Versteeg R., Speleman F. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 2010, 16:4353-4362.
4. George R.E., Sanda T., Hanna M., Frohling S., Luther 2nd W., Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., Look A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
5. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S., Amiel J., Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
6. Janoueix-Lerosey I., Schleiermacher G., Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566-1579.
7. Kim D.Y., Kim S.C., Kim I.K. Neuroblastoma: experience in one center. J. Korean Assoc. Pediatr. Surg. 2005, 11:99-106.
8. Lee C.C., Jia Y., Li N., Sun X., Ng K., Ambing E., Gao M.Y., Hua S., Chen C., Kim S., Michellys P.Y., Lesley S.A., Harris J.L., Spraggon G. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem. J. 2010, 430:425-437.
9. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
10. Martinsson T., Eriksson T., Abrahamsson J., Caren H., Hansson M., Kogner P., Kamaraj S., Schonherr C., Weinmar J., Ruuth K., Palmer R.H., Hallberg B. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 2011, 71:98-105.
11. Matthay K.K., O'Leary M.C., Ramsay N.K., Villablanca J., Reynolds C.P., Atkinson J.B., Haase G.M., Stram D.O., Seeger R.C. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur. J. Cancer 1995, 31A:572-575.
12. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
13. Passoni L., Longo L., Collini P., Coluccia A.M., Bozzi F., Podda M., Gregorio A., Gambini C., Garaventa A., Pistoia V., Del Grosso F., Tonini G.P., Cheng M., Gambacorti-Passerini C., Anichini A., Fossati-Bellani F., Di Nicola M., Luksch R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009, 69:7338-7346.
14. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008, 9:247-256.
15. Sasaki T., Okuda K., Zheng W., Butrynski J., Capelletti M., Wang L., Gray N.S., Wilner K., Christensen J.G., Demetri G., Shapiro G.I., Rodig S.J., Eck M.J., Janne P.A. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010, 70:10038-10043.
16. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 1985, 313:1111-1116.
17. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999, 86:364-372.
18. Tonini G.P., Pistoia V. Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr. Pharm. Des. 2006, 12:2303-2317.
19. Van Roy N., De Preter K., Hoebeeck J., Van Maerken T., Pattyn F., Mestdagh P., Vermeulen J., Vandesompele J., Speleman F. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med. 2009, 1:74.